Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552899 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
NCT04552899 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 665 participants.
The verdict
NCT04552899, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
Study Summary
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG PRM-151 (Zinpentraxin Alfa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04552899
The ClinicalTrials.gov registry entry for NCT04552899 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04552899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04552899 about?
NCT04552899 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis". This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT04552899?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2021-03-19. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT04552899?
The interventions under investigation include: Placebo (DRUG), PRM-151 (Zinpentraxin Alfa) (DRUG).
Who is sponsoring clinical trial NCT04552899?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.